🇩🇪 Germany · EU Public Tender
Vertragsschluss nach 130a Abs. 8 SGB V Arzneimittelbezeichnung: TYSABRI 150 mg Inj.-Lsg.i.e.Fertigspritze 2xSC® Wirkstoff: Natalizumab ATC-Code: L04AA23
🏛️ AOK Bayern – Die Gesundheitskasse · 📍 München
1 €
Estimated value
—
Deadline
| Contract type | Supplies |
| CPV | 33600000 |
| Awarded to | Biogen GmbH |
Full tender details, bidder list, market context and related contracts available below.
Data sourced from TED — the Official Journal of the EU.